menu
    • menu

    Company profile for Atalanta Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Atalanta was founded by world-leading experts in RNA interference to pioneer new treatment options for intractable neurodegenerative diseases. We take our name from the mythological Greek heroine Atalanta, a fierce huntress and, in some accounts, the only woman to sail with the Argonauts in their quest for the Golden Fleece. The protein Argonaute 2 plays an essential role in RNA interference — and like the Argonauts, we are ...
    Atalanta was founded by world-leading experts in RNA interference to pioneer new treatment options for intractable neurodegenerative diseases. We take our name from the mythological Greek heroine Atalanta, a fierce huntress and, in some accounts, the only woman to sail with the Argonauts in their quest for the Golden Fleece. The protein Argonaute 2 plays an essential role in RNA interference — and like the Argonauts, we are visionary and courageous in our exploration of new frontiers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Atalanta TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6 Tide Street, 2nd Floor Boston, MA 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.atalantatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atalanta-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AtalantaTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atalanta Therapeutics Announces Leadership Transitions
    Atalanta Therapeutics Announces Leadership Transitions

    18 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250618351055/en/Atalanta-Therapeutics-Announces-Leadership-Transitions

    BUSINESSWIRE
    18 Jun 2025
    Share Share
    Atalanta Publishes Data on RNAi Therapy for KCNT1-Related Epilepsy
    Atalanta Publishes Data on RNAi Therapy for KCNT1-Related Epilepsy

    08 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250403686093/en/Atalanta-Therapeutics-Publishes-Preclinical-Data-Supporting-Investigational-RNAi-Therapy-for-KCNT1-Related-Epilepsy

    BUSINESSWIRE
    08 Apr 2025
    Share Share
    EQT Lead 75 M Series B in Atalanta for Epilepsy, Huntington Disease
    EQT Lead 75 M Series B in Atalanta for Epilepsy, Huntington Disease

    28 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eqt-life-sciences-leads-usd-75-million-series-b-in-atalanta-therapeutics-a-biotech-firm-developing-treatments-for-epilepsy-and-huntingtons-disease-302361914.html

    PR NEWSWIRE
    28 Jan 2025
    Share Share
    Atalanta Therapeutics Raises $97M To Advance RNAi Therapies For CNS
    Atalanta Therapeutics Raises $97M To Advance RNAi Therapies For CNS

    28 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250128583264/en

    BUSINESSWIRE
    28 Jan 2025
    Share Share
    Atalanta Expands Exec Team With CMO, CFO Appointments
    Atalanta Expands Exec Team With CMO, CFO Appointments

    22 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240522797171/en

    BUSINESSWIRE
    22 May 2024
    Share Share
    Atalanta Tx Appoints Alfred Sandrock to Board of Directors
    Atalanta Tx Appoints Alfred Sandrock to Board of Directors

    10 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220310005237/en

    BUSINESSWIRE
    10 Mar 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search